Pass Our Capabilities- Pages Big-2.png

Helping to advance biomanufacturing


Pass Our Capabilities Pages Small-2.png

At Teva, we’re investing over $500 million dollars to build a new, state-of-the-art biological manufacturing plant in Ulm Germany.

Automated with highly advanced manufacturing technology, this fast, efficient operation will not only allow us to
produce quality biosimilar medicines – it will allow us to do it at a price much lower than originator biologics.


Teva biosimilars Mission: Making Biosimilars accessible to patients who need them

Our mission

Learn how we're making biosimilars more accessible.

Learn more
Teva Capabilities: Finding new ways to unleash value

Our capabilities

See how we’re unleashing value on many fronts.

Learn more
Teva Biosimilar Expertise: Meet the Leaders of Teva

Our expertise

Meet the vanguards leading the way in the new frontier.

Learn more
Teva Biosimilar Products and Partnerships

Our biosimilars

Discover our innovations in the new frontier.

Learn more
Exploring Biosimilars with Teva Biosimilars

Explore biosimilars

Learn why biosimilars are the new frontier.

Learn more